[A20-02] Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76
Last updated 20.03.2020
Project no.:
A20-02
Commission:
Commission awarded on 06.01.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Indication:
Adults treated with apixaban or rivaroxaban when reversal of anticoagulation is needed due to major bleeding
Result of dossier assessment:
Conclusion of dossier assessment A19-76 unchanged: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-76 | Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.